Talk:Deferiprone

cormedix
just a note - today I removed the following: "Deferiprone is in clinical trials in the United States to treat Contrast-Induced Acute Kidney Injury  and to slow progression of Chronic Kidney Disease; the trials are being conducted by the biotech company, Cormedix.(ref)http://www.cormedix.com/pipeline_CRMD001.php(/ref)." This is no longer true - see here http://www.dailyfinance.com/2013/03/27/cormedix-reports-year-end-2012-financial-results/ and here http://philadelphia.citybizlist.com/article/sec-filing-cormedix-terminates-agreement-shiva-biomedical. We should have had some MEDRS compliant source on this and we never did... Jytdog (talk) 10:42, 1 October 2013 (UTC)

Inhibition of HIV-1 gene expression
Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A

Mainul Hoque, Hartmut M Hanauske-Abel, Paul Palumbo, Deepti Saxena, Darlene D'Alliessi Gandolfi, Myung Hee Park, Tsafi Pe'eryEmail author and Michael B Mathews author

Retrovirology 20096:90

DOI: 10.1186/1742-4690-6-90

https://retrovirology.biomedcentral.com/articles/10.1186/1742-4690-6-90


 * Drug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infect ... http://dx.doi.org/10.1371/journal.pone.0154842


 * The finding that the medicinal chelator deferiprone removes, without eliciting viral resistance noticeable in our system, the HIV-1 genome by apoptotic fragmentation preferentially of the infected cells’ DNA, defines a unique antiretroviral profile. However, HIV-1 infection usually is not associated with iron overload, and therefore any as-is repurposing of orally administered deferiprone for its antiretroviral side-activity must not be expected to be benign: We have not shown oral deferiprone to be safe or effective for anti(retro)viral indications.


 * It remains to be established whether any of the currently available oral preparations of deferiprone, or the anticipated chemical optimization of this pioneer drug into non-chelating inhibitors of DOHH, will translate into real benefits for persons living with HIV-AIDS. Based on the preclinical and clinical results presented here and earlier [28,43,45,46], a follow-up clinical trial evaluating the safety, efficacy, and pharmacokinetics of deferiprone in HIV-positive subjects has been conducted and is registered at ClinicalTrial.gov (NCT02456558).


 * http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0154842 — Preceding unsigned comment added by 95.33.229.87 (talk) 19:31, 24 August 2016 (UTC)
 * That is really exciting but it is a primary source and per WP:MEDRS we use literature reviews to source content in WP.  Are you aware of any that discuss the work published in PLoS? Jytdog (talk) 05:00, 25 August 2016 (UTC)